Octreotide · source year
11 selected, source-linked Octreotide records carrying a 2023 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
11 selected records.
2 represented types.
11 distinct public records.
Cited chronology
Regulatory
The official Drugs@FDA dataset lists original submission 1 for ANDA 210317 with status AP dated 2023-12-05, and names octreotide acetate among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Regulatory
DailyMed lists Structured Product Labeling version 1 for the reviewed Octreotide label family with a published date of 2023-12-01. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02381249 at 2026-07-30T19:04:52.219Z. Its registry update date was 2023-11-27, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02385617 at 2026-07-30T19:04:52.214Z. Its registry update date was 2023-11-27, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00427349 at 2026-07-30T19:10:42.711Z. Its registry update date was 2023-07-05, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for ANDA 216839 with status AP dated 2023-06-22, and names octreotide acetate among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00003057 at 2026-07-30T19:11:49.726Z. Its registry update date was 2023-06-18, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00003283 at 2026-07-30T19:11:49.727Z. Its registry update date was 2023-06-15, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for ANDA 216807 with status AP dated 2023-06-13, and names octreotide acetate among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02333565 at 2026-07-30T19:13:03.754Z. Its registry update date was 2023-05-25, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02384122 at 2026-07-30T19:13:03.754Z. Its registry update date was 2023-05-24, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗